rs4958847 — IRGM

Intronic IRGM variant that impairs autophagy-mediated clearance of intracellular bacteria, raising risk for Crohn's disease — particularly ileal disease and fistulizing complications

See your personal result for IRGM

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IRGM rs4958847 — Autophagy Failure at the Gut Frontier

The human gut is in a constant negotiation with bacteria. Most organisms are kept out by the epithelial barrier, but some — including adherent-invasive Escherichia coli (AIEC)11 adherent-invasive Escherichia coli (AIEC)
A pathobiont consistently enriched in the ileal mucosa of Crohn's disease patients, where it penetrates epithelial cells and replicates inside macrophages, evading conventional immune clearance — breach the lining and invade cells directly. The body's main weapon against these intracellular invaders is [autophagy | A cellular recycling process that wraps damaged organelles and intracellular pathogens in double-membrane vesicles called autophagosomes and delivers them to lysosomes for destruction], a process in which IRGM (Immunity-Related GTPase Family M)22 IRGM (Immunity-Related GTPase Family M)
Encodes a GTPase that controls mitochondrial dynamics and serves as a master regulator of selective autophagy, specifically xenophagy (pathogen clearance) and mitophagy (damaged mitochondria elimination) plays a central coordinating role. rs4958847 is a common intronic variant in IRGM that alters the gene's expression level and disrupts this bacterial clearance program, raising the risk for Crohn's disease — particularly the ileal subtype and its most severe complications.

The Mechanism

rs4958847 lies in intron 6 of IRGM (GRCh38 chr5:150860025, G>A) and acts through a regulatory rather than a coding mechanism. The A risk allele is associated with reduced IRGM expression in intestinal epithelial cells and macrophages. When IRGM function is diminished, the autophagy program falters in two distinct ways: intracellular pathogens such as Salmonella, Mycobacterium, and AIEC escape xenophagic destruction and persist in the mucosal compartment; and damaged mitochondria accumulate, releasing reactive oxygen species and pro-inflammatory signals that amplify the innate immune response.

The resulting inflammatory cycle — persistent intracellular bacteria → innate immune activation → epithelial damage → deeper bacterial invasion → more activation — is thought to underlie the transmural, granulomatous inflammation characteristic of ileal Crohn's disease. IRGM also interacts functionally with [ATG16L1 | Autophagy-related protein 16-like 1; the other major autophagy Crohn's gene whose T300A variant (rs2241880) is independently associated with CD susceptibility], and reduced activity of both proteins in the same individual compounds the xenophagy defect.

The Evidence

The IRGM locus was first replicated as a Crohn's disease susceptibility gene33 first replicated as a Crohn's disease susceptibility gene
Parkes et al. 2007 — Nature Genetics 39(7):830-2; genome-wide replication study, combined P=2.1×10⁻¹⁰ in a multi-locus replication analysis. rs4958847 specifically was established as a risk variant through a body of subsequent replication and meta-analysis work.

The most definitive quantification comes from a 2013 meta-analysis of 25 studies44 2013 meta-analysis of 25 studies
Lu et al. 2013 — PLoS One; 20,590 IBD cases and 27,670 controls which found rs4958847 A allele OR=1.18 (95% CI 1.08–1.29, P=0.0002) for CD, surviving Bonferroni correction. Importantly, the association was specific to CD and was not observed for ulcerative colitis, consistent with a mechanism centered on the ileum. A separate pooled analysis by Palomino-Morales et al. 200955 Palomino-Morales et al. 2009
Genes Immun 10(4):356-64; 557 CD, 425 UC patients and 672 controls found rs4958847 A allele OR=1.31 (P=2.78×10⁻¹⁷) for CD.

The effect size is larger in phenotype-restricted analyses. In a New Zealand Caucasian cohort66 New Zealand Caucasian cohort
Roberts et al. 2008 — Genes Immun; 507 CD patients, 475 UC, 576 controls specifically analysing ileal disease, rs4958847 A allele OR reached 1.77 (95% CI 1.22–2.56, P=0.0022), confirming that the risk is concentrated in the ileal subtype. An Italian study by Latiano et al. 200977 Latiano et al. 2009
Am J Gastroenterol; 823 CD patients including 265 paediatric cases and 578 controls found the A allele was associated with fistulizing behavior (OR=1.54, P=0.037) and perianal fistulas (OR=1.55, P=0.045), extending the signal to severe disease complications.

A 2012 surgical outcomes study88 2012 surgical outcomes study
Sehgal et al. — Dis Colon Rectum; 66 ileocolonic CD patients who underwent ileocolectomy found rs4958847 to be the most significant predictor of surgical recurrence: A-allele carriers required reoperation on average every 6.87 years versus 11.43 years for GG individuals (P=0.007), suggesting the variant marks not just susceptibility but ongoing disease severity post-surgery.

Practical Implications

For A-allele carriers with established or suspected Crohn's disease, the IRGM autophagy defect points toward specific management strategies. Monitoring for ileal disease patterns and fistulizing complications is more relevant than for non-carriers. The autophagy connection also opens a specific pharmacological angle: [rapamycin and its analogues | mTOR inhibitors that upregulate autophagy; not currently standard CD therapy but relevant to the mechanistic rationale for existing medications] and several approved immunosuppressants used in IBD (azathioprine, 6-mercaptopurine) stimulate autophagy as part of their mechanism of action, which may partly explain their relevance in IRGM-variant carriers. Anti-TNF biologics are an established treatment for fistulizing CD — the complication subtype most strongly linked to rs4958847.

Interactions

The strongest documented interaction is with [ATG16L1 rs2241880 | T300A missense variant in ATG16L1, the other major autophagy Crohn's gene; A allele is the CD-risk allele at ~45% European frequency]. Both IRGM and ATG16L1 proteins function in the same autophagosome assembly pathway. Studies examining the two variants simultaneously have found additive — and in some analyses synergistic — effects on CD risk. An individual carrying A risk alleles at both rs4958847 and rs2241880 has substantially higher CD risk than either variant alone would predict. The combination is of particular relevance for ileal CD phenotype and post-surgical recurrence risk.

Genotype Interpretations

What each possible genotype means for this variant.

GG Typical IRGM Normal

Common genotype — standard IRGM autophagy function

You carry two copies of the common G allele at rs4958847. This is the lower-risk genotype at this IRGM locus, associated with typical IRGM expression levels and standard autophagy-mediated clearance of intracellular bacteria in the gut. Globally approximately 54% of people carry this genotype; in European populations the frequency is higher (~76%), reflecting the lower A-allele frequency in that ancestry. Your genetic risk for Crohn's disease from this locus is at or below the population average.

AG One Risk Allele Intermediate

One IRGM risk allele — modestly elevated Crohn's disease risk

rs4958847 is an intronic variant in IRGM, located on chromosome 5q33.1. The A allele is associated with reduced IRGM expression in intestinal epithelial cells and macrophages. IRGM normally coordinates the autophagy machinery that wraps and destroys intracellular pathogens — particularly adherent-invasive E. coli and Salmonella — before they can trigger sustained mucosal inflammation. Reduced expression blunts this clearance program.

Under an additive model, heterozygotes carry approximately half the per-allele effect of AA homozygotes. The association is CD-specific (not ulcerative colitis) and is strongest for ileal disease and fistulizing complications. The A-allele frequency is substantially higher in African (47%) and East Asian (54%) than European (13%) populations, meaning the population-attributable risk differs by ancestry.

AA Two Risk Alleles High Risk

Two IRGM risk alleles — meaningfully elevated Crohn's disease and fistula risk

rs4958847 AA homozygosity represents maximal IRGM-related autophagy impairment at this locus. IRGM expression studies in intestinal tissue show that lower IRGM levels correlate with reduced recruitment of autophagy-initiating proteins (ULK1, Beclin-1, WIPI2) to intracellular bacterial compartments. The result is a failure of xenophagy: pathogens such as adherent-invasive Escherichia coli (AIEC) — consistently enriched in ileal Crohn's mucosa — survive and replicate within macrophages instead of being degraded in autolysosomes.

This persistent bacterial survival drives two converging inflammatory processes: activation of NOD2 and TLR signalling pathways (triggering TNF, IL-12, and IL-23 production) and impaired mitophagy (accumulation of damaged mitochondria releasing reactive oxygen species into the cytosol). Together these mechanisms produce the transmural, granulomatous inflammation characteristic of ileal CD.

The surgical recurrence data (Sehgal et al. 2012 — A-allele carriers reoperated every 6.87 vs 11.43 years in GG individuals) suggests the A allele marks ongoing biological susceptibility, not merely disease initiation. This implies that even after surgical resection, the mucosal environment remains permissive to bacterial persistence and re-inflammation.

The strongest interaction partner is ATG16L1 rs2241880 (T300A) — the other major Crohn's autophagy gene. Carriers of risk alleles at both IRGM rs4958847 and ATG16L1 rs2241880 have compounded xenophagy defects and higher CD risk than either variant alone.